Canadian Cancer Trials Group Bulletins

General


The Lancet Oncology publishes iRECIST

A recent publication in The Lancet Oncology highlights the development, led by the RECIST Working Group, of iRECIST (immunotherapy Response Evaluation Criteria in Solid Tumours) consensus-based guideline, which addresses the novel characteristics of this new class of anticancer therapeutics, ensuring consistent trial design and data collection. Read our online story here https://www.ctg.queensu.ca/cctg_news/lancet-oncology-publishes-irecist